Human Pluripotent Stem Cell-Derived Cardiomyocytes as Research and Therapeutic Tools | Zendy

Ivana Aćimović | Zendy; Aleksandra Vilotić | Zendy; Martin Pešl | Zendy; Alain Lacampagne | Zendy; Petr Dvořák | Zendy; Vladimír Rotrekl | Zendy; Albano C. Méli | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Human Pluripotent Stem Cell-Derived Cardiomyocytes as Research and Therapeutic Tools

Author(s) -

Ivana Aćimović,

Aleksandra Vilotić,

Martin Pešl,

Alain Lacampagne,

Petr Dvořák,

Vladimír Rotrekl,

Albano C. Méli

Publication year - 2014

Publication title -

biomed research international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.772

H-Index - 126

eISSN - 2314-6141

pISSN - 2314-6133

DOI - 10.1155/2014/512831

Subject(s) - induced pluripotent stem cell , embryonic stem cell , germ layer , drug discovery , biology , stem cell , cell type , microbiology and biotechnology , cellular differentiation , cell , embryoid body , directed differentiation , computational biology , neuroscience , bioinformatics , genetics , gene

Human pluripotent stem cells (hPSCs), namely, embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), with their ability of indefinite self-renewal and capability to differentiate into cell types derivatives of all three germ layers, represent a powerful research tool in developmental biology, for drug screening, disease modelling, and potentially cell replacement therapy. Efficient differentiation protocols that would result in the cell type of our interest are needed for maximal exploitation of these cells. In the present work, we aim at focusing on the protocols for differentiation of hPSCs into functional cardiomyocytes in vitro as well as achievements in the heart disease modelling and drug testing on the patient-specific iPSC-derived cardiomyocytes (iPSC-CMs).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research